期刊文献+

共载伊立替康-顺铂复合脂质体的制备及质量评价 被引量:1

Preparation and Quality Evaluation of Compound Liposomes of Irinotecan and Cis-platinum
下载PDF
导出
摘要 目的:制备共载伊立替康-顺铂复合脂质体,并对其关键质量指标进行评价。方法:采用薄膜分散和主动载药技术制备目标产品,建立高效液相法测定共载复合脂质体含量及包封率,采用动态光散射法测定粒度和粒度分布。结果:共载伊立替康-顺铂复合脂质体中伊立替康、顺铂包封率分别为(99.51±0.79)%,(98.47±0.91)%(n=3),平均粒径为(129.9±1.9)nm(n=3),多项分散系数(PdI)小于0.20,Zeta电位为(-8.60±0.56)m V(n=3);所制得样品于低温(2~8℃)条件下放置6个月,各项关键指标均未发生明显变化。结论:该方法适合共载伊立替康-顺铂复合脂质体的制备,所建立质控方法简单、准确,适合对该共载复合脂质体质量进行评价。 Objective:To prepare compound liposomes loading irinotecan and cis-platinum,and evaluate the pharmaceutical properties.Methods:Film dispersion-active drug-loading technology was used to load irinotecan and cis-platinum for preparing the compound liposomes.An HPLC method was established for determining irinotecan and cis-platinum.The mean diameter of liposomes was determined by dynamic light scattering(DLS)technique.Results:The encapsulation efficiency of compound liposomes loading irinotecan and cis-platinum was 99.51%±0.79%and 98.47%±0.91%(n=3),respectively.The mean diameter of the compound liposome was(129.9±1.9)nm(n=3)with PdI below 0.20 and its zeta potential was(-8.60±0.56)m V(n=3).The inspection indices of the compound liposomes did not change significantly in 6 months of long-term storage test(2℃~8℃).Conclusion:The method is suitable to prepare compound liposomes of irinotecan and cis-platinum.The analysis method is simple and accurate,which can be used to evaluate the properties of the compound liposomes.
作者 张登山 刘留成 Zhang Dengshan;Liu Liucheng(Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029,China;Jiangsu Aosaikang Pharmaceutical Co.Ltd.)
出处 《中国药师》 CAS 2020年第2期280-284,共5页 China Pharmacist
关键词 伊立替康 顺铂 脂质体 制备 质量评价 稳定性 Irinotecan Cis-platinum Liposomes Preparation Quality evaluation Stability
  • 相关文献

参考文献10

二级参考文献68

  • 1罗志国,冯奉仪,王兴元,张频.小细胞肺癌骨髓转移29例临床分析[J].实用癌症杂志,2004,19(6):609-611. 被引量:5
  • 2李高峰,蒋永新,王巍炜,巫正伟,郭刚.肺癌术后过继免疫治疗的近期疗效分析[J].肿瘤研究与临床,2007,19(2):99-100. 被引量:2
  • 3GABIZON A, SHMEEDA H, BARENHOLZ Y. Pharmacokinet- ics of PEGylated liposomal doxorubicin :review of animal and hu- man studies [ J ]. Clin Pharmacokinet,2003,42 ( 5 ) : 419 - 436.
  • 4BARENHOLZ Y. Liposome application: problems and prospects [J]. Curr Opin Colloid Interface Sci,2001,6( 1 ) : 66 -77.
  • 5BOLOTIN EM, COHEN R, BAR LK, et al. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes [ J ]. J Liposome Res, 1994,4(1) :455 -479.
  • 6DRUMMOND DC, MEYER O, HONG K, et al. Optimizing li- posomes for delivery of chemotherapeutic agents to solid tumors [ J ]. Pharmacol Rev, 1999,51 (4) :691 - 742.
  • 7BARENHOLZ Y. Doxil-the first FDA-approved nano-drug: les- sons learned[J]. J Control Release,2012,160(2) :117 - 134.
  • 8FDA. Guidance for industry: liposome drug products chemistry, manufacturing, and controls, human pharmacokinetics and bio- availability, and labeling documentation [ EB/OL ]. (2013 - 03 - 18 ). http://www, fda. gov/downloads/drugs/guidancecompli- anceregulatoryinformation/guidances/ucm070570, pdf.
  • 9FDA. Guidance for industry : bioequivalence recommendations for specific products: draft guidance on doxorubicin hydroch|oride [ EB/OL]. (2012 - 06 - 08 ). http://www, fda. gov/down- loads/drugs/guidancecomplianceregulatoryinformation/guidances! ucm199635, pdf.
  • 10EMA. Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator lipo- somal productE EB/OL]. (2013 - 02 - 21 ). http://ema, euro- pa. eu/docs/en-GB/doeument-libraay/Scientific-guideline/2013/ 03/WC500140351. pdf.

共引文献68

同被引文献11

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部